VERAXA Biotech Begins NASDAQ Trading After Voyager Acquisition Deal
VRXA•Veraxa Biotech completed a business combination with Voyager Acquisition Corp and commenced trading on the NASDAQ Capital Market under VRXA on June 11, 2026. The company has a diversified oncology pipeline featuring monoclonal antibodies, ADCs, bispecific ADCs, TCEs and a proprietary BiTAC platform targeting multiple tumor indications.
1. SPAC Merger and NASDAQ Listing
Veraxa Biotech closed its business combination with Voyager Acquisition Corp on June 11, 2026 and began trading on the NASDAQ Capital Market under the ticker VRXA, securing capital to advance its oncology programs.
2. Diversified Oncology Pipeline
The company is developing a range of antibody-based therapeutics including monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and T-cell engager formats across multiple solid tumor indications.
3. Proprietary BiTAC Platform
Veraxa’s BiTAC platform is engineered to conditionally activate therapeutic agents at tumor sites, aiming to enhance target specificity and minimize off-tumor toxicity in cancer treatment.
4. Strategic Partnerships in RIC and AOC
Selected collaborations in radioimmunoconjugates and antibody-oligonucleotide conjugates extend Veraxa’s reach into complementary oncology modalities and may accelerate its therapeutic development pipeline.
